Alerta

ANTIVIRALS TARGETING PHOSPHATIDIC ACID PHOSPHATASE (PAP)

Resumen de: US2025064758A1

Host-targeting antiviral agents against conserved phosphatidic acid phosphatase (PAP) pathways that act as broad-spectrum treatment strategies for different coronaviruses, such as variants of SARS-COV-2, have been developed. Compositions of anti-coronavirus agent(s) that acts via the host PAP pathway and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. An exemplary anti-coronavirus agent that acts via the PAP pathway is propranolol. Compositions of propranolol and methods of use thereof for treating and preventing diseases and disorders associated with coronaviruses are provided. In some forms, the compositions and methods treat or prevent one or more symptoms associated with infection by SARS-COV-2 wild type, Delta variants, Omicron variants and MERS-COV in a subject in need thereof.

ANTI-HUMAN CORONAVIRUS COMPOSITION

Resumen de: EP4512255A1

An objective of the present invention is to provide a nonpharmaceutical anti-human coronavirus composition that prevents human coronavirus infections, the onset of the infections, or aggravation of symptoms of the infections. The anti-human coronavirus composition according to the present invention includes an exopolysaccharide produced by a lactic acid bacterium in genus Lactobacillus as an active component. The lactic acid bacterium in the genus Lactobacillus may belong to a Lactobacillus delbrueckii species. The lactic acid bacterium in the genus Lactobacillus may specifically be Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).

COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19

Resumen de: US2024166587A1

The invention discloses a compound with the general formula (I) wherein R1 to R6 are identical or not and are H, OH—, or OR7, wherein R7 is a C1 to C3 alkyl group or a C1 to C4 acyl group, with the proviso that at least four of R1 to R6 are different than H, for use in the treatment and prevention of COVID-19 in a human subject, especially for inhibiting SARS-CoV-2.

METHOD FOR OPTIMIZING VIRUS MEMBRANE FUSION INHIBITOR, BROAD-SPECTRUM ANTI-CORONAVIRUS LIPOPEPTIDE AND USE THEREOF

Resumen de: ZA202403797B

Provided are a broad-spectrum anti-SARS-CoV-2 lipopeptide, a preparation method therefor, a virus membrane fusion inhibitor comprising the lipopeptide, and use of the lipopeptide in the preparation of a pharmaceutical composition for preventing and treating diseases caused by the coronavirus. The structure of the lipopeptide is shown as formula (I) or formula (II), wherein X1 is an amino protection group; X2 is a polypeptide, whose amino acid sequence is (EAAAK)n or A(EAAAK)nA, wherein n is a natural number less than 5 and indicates the number of repetitions of the EAAAK sequence; X3 is lysine or cysteine or 2,3-diaminopropionic acid or ornithine or 2,4-diaminobutanoic acid or 2,7-diaminoheptanoic acid; X4 is a lipophilic compound group; X5 is a carboxy-terminal protecting group.

ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS

Resumen de: US2025057927A1

A recombinant alphal-antitrysin (AAT) protein or a fragment thereof expressed in a genetically modified yeast for use in the treatment of a viral infection and/or lung inflammation. In one embodiment, the viral infection is a viral respiratory infection, preferably a coronavirus infection, such as a SARS CoV infection, more preferably SARS-CoV-2. Also disclosed is a method of producing recombinant AAT protein or fragment(s) thereof from genetically modified yeast. In embodiments, the method includes the steps of culturing a genetically modified yeast comprising an exogenous nucleic acid molecule with an AAT-encoding region operably linked to a promoter or promoter/enhancer combination, expressing recombinant AAT in the cultured yeast, and isolating recombinant AAT from the culture. In embodiments, the recombinant AAT produced from yeast is prepared in a pharmaceutical composition, such as a solution, preferably suitable for nebulization and subsequent inhalation by a subject.

PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB

Resumen de: WO2025036230A1

The present invention relates to the field of medicine, and in particular to a protein, adenovirus and vaccine against infection of a subtype of SARS-CoV-2 Omicron mutant strain XBB. In order to solve the problem of lack of effective prevention and treatment drugs against infection of SARS-CoV-2 Omicron mutant strain XBB and a subtype thereof, the present invention provides a protein, adenovirus and vaccine against the infection of the subtype of the SARS-CoV-2 Omicron mutant strain XBB. The vaccine is designed by optimizing the sequences of full-length S proteins of sub-lines XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2 of the SARS-CoV-2 Omicron mutant strain XBB, and RBD and RBD-HR sequences in the S proteins, can help a host to resist coronavirus infection, and in particular has a good prevention and treatment effect on cross infection caused by subtype viruses of the Omicron mutant strain XBB.

IMMUNE MEMORY ENHANCED PREPARATIONS AND USES THEREOF

Resumen de: US2025057940A1

Formulations and preparations having immune memory enhanced properties are disclosed that provide for enhancing immune response against a tumor growth, cancer, infectious agent, bacteria, virus or other infectious or non-infectious agent. The vaccine formulation includes an immune memory invoking component, such as an antigen of an infectious agent, virus (e.g., Rabies), bacteria, prion, neo-antigen or other moiety antigen, and a targeted antigen (e.g., a harvested tumor tissue (B-cell, T-cell, epitopes)). The vaccine formulation/preparations may comprise a target infectious agent protein/peptide component (such as a SARS-Cov-2 spike protein epitope) mixed with, or fused to (or otherwise conjugated) an immune-memory associated viral antigen (such as Rabies, polio, or other peptide/protein antigen or peptide or fragment thereof).

PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: US2025057803A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided. In alternative embodiments, provided are therapeutic combinations of drugs or a drug, a pharmaceutical dosage form, a drug delivery device, or a product of manufacture, comprising: opaganib or YELIVA™, or opaganib or YELIVA™ and oral and/or inhaled chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate and/or hydroxychloroquine (optionally, PLAQUENIL™), with or without azithromycin, wherein optionally each or all of the opaganib, the chloroquine (or ARALEN™), chloroquine phosphate, chloroquine diphosphate an

APPLICATION OF 10'(Z), 13'(E), 15'(E)-HEPTADECATRIENYL HYDROQUINONE (HQ17(3)) IN TREATING CORONAVIRUS INFECTION

Resumen de: US2025057785A1

The present disclosure relates to use of 10′(Z), 13′(E), 15′(E)-Heptadecatrienyl hydroquinone compound (hereafter “HQ17(3)”) represented by the following Formula (12), a pharmaceutically acceptable salt, and/or a solvate and/or a hydrate thereof, and a pharmaceutical composition comprising the above compound, in treating coronavirus infection and diseases caused by the infection, especially SARS-COV-2 infection.

METHOD AND REAGENT FOR TESTING NOVEL CORONAVIRUS

Resumen de: US2025059613A1

A method for testing a novel coronavirus, the method including steps of: mixing a specimen sample collected from a subject, or a mixed liquid of the specimen sample and a medium, with a specimen treatment liquid containing sodium hydroxide as a main component, to obtain a mixed liquid; incubating the mixed liquid; adding a master mix containing a reaction liquid, an internal standard substance, a primer, a probe, a reverse transcriptase, and a PCR enzyme to the mixed liquid after the incubation, to obtain a final mixed liquid; subjecting the final mixed liquid to a reverse transcription reaction treatment; and detecting, through use of the probe, DNA amplified by PCR using the DNA generated by the reverse transcription reaction treatment as a template.

LIGANDS AND METHODS OF MAKING LIGANDS FOR AFFINITY CAPTURE ON A SURFACE OF MRNA IN A SOLUTION

Resumen de: US2025059528A1

Separation constructs such as membranes, porous beads, etc. are modified with a plurality of oligomeric ligands. The ligands are bound to the surface of the separation substrates via linker constructs such as acrylate groups or azide groups, e.g., via Single-Electron Transfer-Living Radical Polymerization (SET-LRP). A plurality of spacer constructs, such as polyethyleneglycol (PEG) groups and hydrocarbyl groups, separate the linker constructs from oligomer constructs. The oligomer constructs can include between 5% and about 10% guanine and about 90% to about 95% thymine, and can further include between about 20 and about 60 nucleotides including at least 15 thymines and at least 1 guanine. The oligomer constructs exhibit improved binding of mRNA with oligo-dAn tails, e.g., for purification of mRNA production and commercialization, enabling fast, efficient, and continuous production of mRNA vaccines such as those against coronaviruses, e.g., SARS-CoV-2.

PLPRO INHIBITORS

Resumen de: US2025059159A1

Provided herein are novel compounds (e.g., Formula X or Y), pharmaceutical compositions, and methods of using the same. The compounds herein can typically inhibit PLpro activities. The compounds herein can also be used for treating a variety of diseases or disorders, such as viral infection caused by a coronavirus such as SARS-CoV-2.

PSEUDOVIRUS BASED NEUTRALIZATION ASSAY FOR EVALUATING VACCINE IMMUNOGENICITY

Resumen de: AU2023315949A1

Provided herein are pseudoviruses expressing a SARS-CoV-2 S glycoprotein. Also provided herein are assays that employ the pseudoviruses to evaluate the immunogenicity of a biological sample against a SARS-CoV-2 virus or variant thereof. Also provided herein are methods of evaluating the immunogenicity of a COVID-19 vaccine using the assays.

SARS-COV-2 PLPRO INHIBITORS AND METHODS OF USE THEREOF

Resumen de: WO2025038464A1

Papain-like protease (PLpro) inhibitors are described herein. The disclosed PLpro inhibitors feature an oxirane-containing warhead and can covalently bind in the active site of PLpro. These PLpro inhibitors show an improved potency (i.e., an IC50 value down to about 0.4 nM). The potency of the disclosed PLpro inhibitors outperforms previously reported PLpro inhibitors, such as GRL0617, and non-covalent PLpro inhibitors. Pharmaceutical compositions containing the PLpro inhibitors are also described. Methods of using the PLpro inhibitors or the pharmaceutical compositions for preventing or treating diseases and/or disorders caused by a coronavirus are also described.

USE OF THERAPEUTIC PEPTIDES

Resumen de: US2025059233A1

Peptides and pharmaceutically acceptable salts thereof and peptide conjugates and pharmaceutically acceptable salts thereof having 5 to 15 amino acids and having an amino acid sequence comprising at least 5 consecutive amino acids from the amino acid sequence LSSTQAQQSX1 (SEQ ID NO:1) for use in treating a subject suffering from or at risk of an inflammatory disease or disorder, schizophrenia or psychosis, a neurodegenerative disease such as Parkinson's disease. Alzheimer's disease, or ALS, a gastrointestinal disease or disorder such as irritable bowel syndrome, inflammatory bowel disease. Crohn's disease, or constipation, pain (e.g., visceral pain), rheumatoid arthritis, migraine, headache, substance abuse (e.g., substance use disorder such as drug use disorder, polysubstance use disorder, alcohol use disorder, or nicotine use disorder, tobacco use disorder), drug addiction, a seizure disorder, major depressive disorder, atypical depression, a major depressive episode (MDE) (e.g., atypical MDE), treatment resistant depression, depression in the presence of a neurodegenerative disease, cognitive impairment, COVID-19 related cognitive impairment and/or depression, ADHD, an autism spectrum disorder, a pervasive developmental disorder, atypical autism, multiple sclerosis, PTSD, a sleep disorder such as insomnia, daytime fatigue, or REM sleep behavior disorder, or for use in improving sleep in a subject.

ANTISENSE OLIGONUCLEOTIDES (ASOS) THAT SUPPRESS SARS-COV-2 REPLICATION

Resumen de: US2025059544A1

Provided herein are antisense oligonucleotides for use in targeting SARS-CoV-2. Also provided herein are compositions comprising such oligonucleotides and methods for administering the oligonucleotides or compositions thereof to a subject for the purpose of treating or preventing a SARS-CoV-2 infection.

METHOD OF DETECTION OF SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-COVID (SARS-CoV)

Resumen de: US2025062038A1

A method of detecting SARS-COV in a sample includes contacting a metal-organic framework with at least one fluorophore-labeled single-stranded probe deoxyribose nucleic acid (DNA) to form a biosensor. The metal-organic framework of the method is zeolitic imidazolate framework-8 (ZIF-8), and the fluorophore-labeled single-stranded probe DNA (p-DNA) has a fluorescence signal at 513 to 517 nm. The method further includes contacting the sample with the biosensor in a solution, and the sample comprises a target sequence of SARS-COV. The target sequence of SARS-COV and the fluorophore-labeled single-stranded p-DNA of the method hybridize to form a double-stranded product. Following the step of the hybridization forming the double-stranded product, the method includes detecting the double-stranded product by observing a change in fluorescence.

CORONAVIRUS VACCINE

Resumen de: AU2025200483A1

Abstract This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject. In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into th

SARS-COV2 MAIN PROTEASE INHIBITORS

Resumen de: AU2023320566A1

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

ACE2 INHIBITION ASSAY FOR EVALUATION OF VACCINE IMMUNOGENICITY

Resumen de: AU2023314769A1

An improved assay to measure immunogenicity of vaccines while overcoming some of the limitations of current biomarkers of immunogenicity is necessary. Disclosed herein is an assay for measuring inhibition of binding between SARS-CoV-2 Spike (S) glycoproteins and hACE2. Also provided herein are methods of using the assay to evaluate the efficacy of COVID-19 vaccines.

FREEZE-DRIED VIRAL COMBINATION VACCINE COMPOSITIONS AND PROCESS FOR PREPARATION THEREOF

Resumen de: US2025057939A1

The present disclosure relates to field of lyophilized/freeze-dried viral combination composition/formulation and methods for manufacturing and obtaining the composition comprising at least three live attenuated virus selected from a group of Coronavirus, Measles virus and Rubella virus; and stabilizers comprising of at least one carbohydrate, at least one amino acid and at least one hydrolyzed protein. The said lyophilized/freeze-dried viral combination composition/formulation is a vaccine composition that preserves the desired characteristics of each virus, including stability and immunogenicity. The composition can be safely administered subcutaneously as a combination vaccine composition such that the immunogenicity of each of the measles, rubella and SARS-CoV-2 is not inferior to that observed for each of the three viruses when administered as individual vaccines and is found to be equivalent or improved as compared to immunogenicity of SARS-CoV-2 vaccine given intranasally. The purification process is devoid of chromatography steps.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Resumen de: US2025057942A1

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

DYSREGULATION OF TRAUMA REGULATION PATHWAY TREATMENT AND MONITORING TECHNIQUES

Resumen de: US2025057941A1

The subject matter of the present disclosure generally relates to techniques for addressing or correcting dysregulation of the trauma regulation pathway. The dysregulation may be associated with a physiological condition, such as a SARS-CoV-2 viral infection. In an embodiment, the techniques include treating dysregulation based on a renin-angiotensin pathway molecule or cell and/or a splenic pathway molecule or cell using targeted neuromodulation. In an embodiment, neuromodulation is used to regulate the immune system, e.g., as an energy-based adjuvant for a vaccine.

METHODS OF PREVENTING OR TREATING INFECTION BY RESPIRATORY VIRUSES INCLUDING SARS-COV-2

Resumen de: US2023374153A1

Methods and compositions to treat or prevent infections by respiratory virus, including SARS-CoV-2 (COVID-19). Included are chimeric antibodies comprising an immunoglobin region having an Fc domain that does not bind FcγRs and/or C1q, e.g. having substitutions L234S, L235T, G236R (STR), and an ACE2 domain having high affinity binding to a plurality of viral variants, e.g. having substitutions T27L or T27Y, H34V, N90E (LVE or YVE). The antibodies may have increased binding to FcRn, e.g. having substitutions M252Y, S254T, and T256E (YTE). The antibodies can be administered intranasally, by respiratory nebulization or systemically to treat or prevent respiratory viral infections.

SYSTEMS AND METHODS FOR PREDICTING COVID-19 CASES AND DEATHS

Nº publicación: EP4508659A1 19/02/2025

Solicitante:

HOFFMANN LA ROCHE [CH]
ROCHE DIAGNOSTICS GMBH [DE]
F. Hoffmann-La Roche AG,
Roche Diagnostics GmbH

Resumen de: US2025014765A1

A machine learning and/or deep learning framework forecasts epidemic or pandemic cases and deaths. Multiple open data sources relevant for the pandemic or epidemic evolution in a geographic area, such as the United States or another country or region, can be processed to extract a plurality of features, such as localized (i.e., county level, city level, regional level, province level, etc.) cases and deaths, demographics and socioeconomic factors, non-medical interventions, and mobility (i.e., from cell phone and/or GPS data). The learning can be used to predict future cases and deaths at localized levels and to recommend healthcare resources that may be needed.